Sparrow Pharmaceuticals
PORTLAND, Oregon · Healthcare, Health Care
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.
Key facts
- Headquarters
- PORTLAND, Oregon
- Employees
- Unknown
- Industries
- Healthcare, Health Care
- Status
- Private
- Website
- https://sparrowpharma.com
- Company page
Recent activity at Sparrow Pharmaceuticals
- : Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer
- : Sparrow Pharmaceuticals raises $95M in Series B financing co-led by RA Capital Management and Forbion to develop clofutriben for type 2 diabetes treatment.
- : Sparrow Pharmaceuticals
- : Sparrow Pharmaceuticals
- : Sparrow Pharmaceuticals Secures $50 Million Series A Financing
- : Sparrow Pharmaceuticals, Inc.
- : Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series B | $95.0M |
| Jul 2025 | Venture | $61.8M |
| Apr 2024 | Venture | $10.0M |
| May 2021 | Series A | $50.0M |
| Jan 2021 | Seed | $1.1M |
Leadership
- Robert Jacks, Executive Officer, Director
- David Katz, Executive Officer, Director
- George Eldridge, Chief Financial Officer
- Klaus Veitinger, Director
- Peter Thompson, Director
- Jonathan Root, Director
- Niall O'Donnell, Director
- Robert Jacks, Executive Officer
- Klaus Veitinger, Director
- Peter Thompson, Director
- Jonathan Root, Director
- Niall O'Donnell, Director
Verified email and direct lines for Sparrow Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Sparrow Pharmaceuticals in the news
- Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes - GlobeNewswire (Sep 24, 2025)
- Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer - markets.businessinsider.com (Sep 08, 2026)
- Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s Syndrome - BioSpace (Oct 28, 2024)
- Sparrow Pharmaceuticals to Present Phase 2a Results for - GlobeNewswire (May 29, 2026)
Companies similar to Sparrow Pharmaceuticals
- EyePoint Pharmaceuticals, Inc. · Healthcare, Health Care
- Shoulder Innovations · Healthcare, Health Care
- OptimizeRx · Healthcare, Health Care
- Flyte · Healthcare, Health Care
- ADARx Pharmaceuticals, Inc. · Healthcare, Health Care
About Sparrow Pharmaceuticals: questions and answers
What does Sparrow Pharmaceuticals do?
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.
Where is Sparrow Pharmaceuticals headquartered?
Sparrow Pharmaceuticals is headquartered in PORTLAND, Oregon.
Has Sparrow Pharmaceuticals raised funding?
Yes. Fundz has recorded 5 funding events for Sparrow Pharmaceuticals. The most recent, Series B of $95.0M, was in Sep 2025.
What is the latest news on Sparrow Pharmaceuticals?
On Sep 09, 2026, Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy